Pierrel acquired the 100% of Hyperphar Group and its subsidiaries Farma Resa spa and Hyperphar Group Germany, as well as the 35% of the Dutch company Hyperphar Research Benelux Bv. The price was set at a maximum equity value of 8.7 million, paid for 6.3 million at the closing of the transaction and for 2.4 million through a deferred payment to be made on the basis of the 2007 result. In detail, Pierrel noted 55.55% from the shareholder and Luigi Visani (who took over Pierrel's 2% and will join the board of directors from February) and 35% from Wise Sgr, through the Wisequity fund.
